Supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Interstitial lung disease (ILD) presents a unique and difficult challenge in the hospital setting due to the chronic nature of the precipitating condition. Studies have shown that elderly patients and patients in long-term care settings with ILD are significantly more likely to be hospitalized than patients without. In general, the progressive restrictive-ventilatory limitation, hypoxia, dyspnea, and cough typically observed in patients with an ILD are associated with significant quality of life (QOL) impairments and, in some cases, can result in death from respiratory failure. Therefore, there is a need for clinicians practicing in a hospital setting to possess adequate knowledge of ILD incidence, the skills to perform a differential diagnosis, and provide adequate management and treatment that is effective upon a patient’s return to the community or long-term care setting. This program aims to address these important clinical needs.
This educational initiative has been designed for pulmonologists, internal medicine physicians, and physicians in training involved in the care of patients with ILD.
Upon completion of this educational activity, participants should be able to:
Outline a multidisciplinary approach for the differential diagnosis of ILD
Discuss the latest evidence-based guidelines for idiopathic pulmonary fibrosis (IPF) and review strategies for individualized management of patients with ILD
Describe strategies for ensuring adequate communication between clinicians and patients over the course of ILD management
Conflict Of Interest Disclosure Policy
Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent COI they may have as related to the content of this activity. All identified COI are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The following faculty/planners reported their financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Lisa H. Lancaster, MD Associate Professor Division of Allergy, Pulmonary, and Critical Care Medicine Vanderbilt University Medical Center Nashville, TN
Dr. Lancaster discloses the following: Consultant: Boehringer Ingelheim Pharmaceuticals, Inc., Genentech Contracted Research: Boehringer Ingelheim Pharmaceuticals, Inc., Celgene, Genentech, Global Brand Therapeutics
Steven D. Nathan, MD Medical Director Lung Transplant Program Director Advanced Lung Disease Program Inova Fairfax Hospital Fairfax, VA
Dr. Nathan discloses the following: Consultant: Bayer Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, Inc., Roche-Genentech Contracted Research: Boehringer Ingelheim Pharmaceuticals, Inc., Roche-Genentech
Accredited Provider Disclosure
Patima Tanapat, PhD, has no real or apparent conflicts of interest to disclose.
AMA PRA Category 1 Credit(s)TM
Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.
Integrity Continuing Education designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Boehringer Ingelheim Pharmaceuticals, Inc., do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Inc., and Boehringer Ingelheim Pharmaceuticals, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.
There are no fees for participating and receiving CME credit for this activity. During the period of October 6, 2017 through October 6, 2018, participants must:
Read the learning objectives and faculty disclosures
Complete the pre-test
Study the educational activity
Complete the post-test and the evaluation form
A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 100%.
For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or email@example.com.